You are here: Industry Insights > GBM

News List

Nanoform Signs GMP Manufacturing Program with TargTex contractpharma
February 04, 2022
Aims to enhance TargTex’s Glioblastoma multiforme drug candidate.
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day Kazia
July 22, 2021
Kazia Therapeutics Limited yesterday recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.
Curtana and Catalent Enter Brain Cancer Drug Partnership contractpharma
July 19, 2021
Curtana has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana’s CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.
Cancer vaccine shows promise in glioblastoma trial europeanpharmaceuticalreview
June 11, 2021
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
Imvax Appoints Sean Hemingway Chief Operating Officer contractpharma
April 09, 2021
Imvax, Inc., a developer of immunotherapy for Glioblastoma (GBM) and other cancers, has appointed Sean Hemingway as Chief Operating Officer.
BERG to Conduct Phase Two Trial for Glioblastoma Multiforme americanpharmaceuticalreview
March 29, 2021
BERG announced the U.S. Federal Drug Administration (FDA) has authorized a phase 2 trial in glioblastoma multiforme (GBM) patients in neo-adjuvant settings using BERG's BPM 31510.
First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma americanpharmaceuticalreview
January 15, 2021
Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ...
FDA Approves IND Application for Brain Cancer Drug Candidate americanpharmaceuticalreview
January 07, 2021
CNS Pharmaceuticals announced the Investigational New Drug (IND) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM) is now approved and in effect as filed with the US Food and Drug Administration ...
Kintara, GCAR Execute Agreement for VAL-083's Participation in the GBM AGILE Study americanpharmaceuticalreview
October 28, 2020
Kintara Therapeutics announced the execution of an agreement with the Global Coalition for Adaptive Research (GCAR) for VAL-083's participation in GCAR's Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study.
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin contractpharma
October 22, 2020
Phase 2 trial will commence during the first quarter of 2021.

Previous page 1 2 Next page